AMGN · News · 20261105N

Repatha Cardiovascular Outcomes Data

AMGEN INC · 2026-11-05 · Importance 35 · Surprise 48

A real-world study of more than 544,000 adults with atherosclerotic cardiovascular disease (ASCVD) and prior statin use found that Repatha (evolocumab) reduced the risk of fatal or nonfatal heart attacks by 20% compared with ezetimibe. Participants were followed for up to four years. The findings add comparative outcomes evidence for Repatha in non-statin treatment decisions for patients with ASCVD.

Key facts

• In a real-world study, Repatha (evolocumab) reduced the risk of fatal or nonfatal heart attacks by 20% compared with ezetimibe in people with ASCVD and prior statin use. source
• The study followed more than 544,000 adults for up to four years. source
• The study findings were published in The American Journal of Preventive Cardiology. source